U.S. Congress legislation · 119th Congress
HB10150: Advancing Botanical Drug Development Act of 2026
Status: In committee, August 27, 2026
To amend the Federal Food, Drug, and Cosmetic Act to provide a period of market exclusivity for botanical drugs, and for other purposes.
What the bill says
To amend the Federal Food, Drug, and Cosmetic Act to provide a period of market exclusivity for botanical drugs, and for other purposes.
From the introduced text, August 27, 2026:
A BILL To amend the Federal Food, Drug, and Cosmetic Act to provide a period of market exclusivity for botanical drugs, and for other purposes. SECTION 1. Short title This Act may be cited as the Advancing Botanical Drug Development Act of 2026 . SECTION 2. Findings Congress finds the following: (1) Chronic and age-related diseases are among the leading causes of disability, impaired quality of life, and health care spending in the United States. (2) Many chronic and age-related diseases involve multiple biological pathways and complex pathophysiology, yet most currently approved therapies are designed to target a single molecular pathway. (3) Botanical drugs regulated by the Food and Drug Administration (in this section referred to as the FDA ) under section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 ) may contain multiple naturally occurring active constituents capable of acting on multiple biological pathways simultaneously and safely. (4) Since the FDA established a regulatory pathway for botanical drugs in 2004, only a limited number of botanical drugs have received approval, despite significant scientific and therapeutic potential and the growing interest of patients in evidence-based, FDA-approved treatment options derived from natural products. (5) In addition to the costs associated with the clinical development of conventional synthetic drugs, botanical drugs present unique scientific and manufacturing challenges …
Sponsors
- Lauren Boebert (R, HD-004) · primary sponsor
- Derrick Van Orden (R, HD-003)
Latest actions
- : Referred to the House Committee on Energy and Commerce.
- : Introduced in House
Subjects: Health
Common questions
- What is HB10150?
- HB10150 is a bill in Congress (119th Congress): Advancing Botanical Drug Development Act of 2026.
- What does HB10150 do?
- In its own words: To amend the Federal Food, Drug, and Cosmetic Act to provide a period of market exclusivity for botanical drugs, and for other purposes.
- What is the status of HB10150?
- In committee as of August 27, 2026. Latest action: Referred to the House Committee on Energy and Commerce. (August 27, 2026).
- Who sponsored HB10150?
- Lauren Boebert (R, HD-004), with 1 co-sponsor.
- Where is the official record for HB10150?
- On the Congress website: https://www.congress.gov/bill/119th-congress/house-bill/10150
Source: official Congress record. Tracked by Delilah, AI for legislation across all 50 states and Congress.